Alder BioPharmaceuticals (ALDR) Shares are Down -3.53%

Alder BioPharmaceuticals (ALDR) has risen sharply, recording gains of 3.97% in the past 4 weeks. However, the stock has corrected -3.53% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.53% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.64% and the 50-Day Moving Average is 3.88%.The 200 Day SMA reached 19.62%


Alder BioPharmaceuticals (NASDAQ:ALDR): After opening at $31.64, the stock dipped to an intraday low of $31.01 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $33.0685 and the buying power remained strong till the end. The stock closed at $32.77 for the day, a gain of 4.73% for the day session. The total traded volume was 668,026. The stocks close on the previous trading day was $32.77.

Alder BioPharmaceuticals (ALDR) : The consensus price target for Alder BioPharmaceuticals (ALDR) is $47 for the short term with a standard deviation of $10.23. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $62, however, the pessimist price target for the company is $40.

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.